Familial Partial Lipodystrophy Type 5 (FPLD5)

Familial partial lipodystrophy type 5 (FPLD5) is a very rare genetic disease where fat under the skin (subcutaneous fat) is lost from some parts of the body but kept or even increased in other parts. In FPLD5, fat is mainly missing from the legs, buttocks and lower trunk, while fat in the inside of the belly (visceral fat) and around the neck and armpits is often kept. This gives a mixed body shape, with thin legs and a more rounded middle part of the body.

Familial partial lipodystrophy type 5 (FPLD5) is a very rare genetic disease where a person loses normal fat from some parts of the body but keeps or gains fat in other places. It is usually caused by mutations in a gene called CIDEC, which helps fat cells store fat safely. When this gene does not work properly, subcutaneous fat in the legs, buttocks and lower abdomen is reduced, but fat around internal organs, neck and armpits is preserved or increased. This uneven fat distribution is often associated with serious metabolic problems such as insulin-resistant type 2 diabetes, very high triglycerides, fatty liver, high blood pressure and pancreatitis.[1]

FPLD5 is caused by changes (mutations) in a gene called CIDEC, which stands for “cell death-inducing DFFA-like effector C.” This gene helps fat cells store fat correctly inside small fat droplets. When the CIDEC gene does not work properly, fat cells cannot join and grow their fat droplets, so they cannot store fat in the normal way.

Because fat is not stored well under the skin, it moves to other places like the liver and inside the belly. This abnormal fat storage can lead to insulin resistance (the body does not respond well to insulin), type 2 diabetes, high blood fats (especially triglycerides), and fatty liver disease. Over time, these problems can cause high blood pressure, pancreatitis (inflammation of the pancreas), enlarged liver, and other serious health issues.

FPLD5 is inherited in an autosomal recessive way. This means a person usually needs to receive a non-working copy of the CIDEC gene from both parents to get the disease. Parents who each carry one non-working copy usually do not have clear symptoms, but they can pass the gene to their children.

Only a very small number of people with FPLD5 have been reported in the medical literature. Because it is so rare and looks like other types of familial partial lipodystrophy, many cases may be missed or called by a more general name such as “familial partial lipodystrophy” without the subtype.

Other names

FPLD5 has several other names used in medical books and databases. It may be called CIDEC-related familial partial lipodystrophy, familial partial lipodystrophy associated with CIDEC mutations, or simply CIDEC-related FPLD. All these names describe the same condition where changes in the CIDEC gene cause a specific pattern of fat loss and metabolic problems.

Some disease catalogs also use ID codes such as OMIM 615238 or Orphanet 435651 for this condition. These codes help doctors and researchers link information about the disease, including genetics, clinical signs, and laboratory findings, across different databases.

FPLD5 is one subtype within the broader group called familial partial lipodystrophy (FPLD). Several main types have been described, based on which gene is changed:

• FPLD1 – Kobberling type, gene not yet clearly identified.

• FPLD2 – Dunnigan type, usually due to changes in the LMNA gene.

• FPLD3 – due to changes in the PPARG gene.

• FPLD4 – linked to PLIN1 gene changes.

• FPLD5 – the type discussed here, due to CIDEC gene mutations, usually autosomal recessive.

• FPLD6 and other newer types – linked to other genes such as LIPE, AKT2, CAV1 and more, but often described in only a few families.

All these types share the core problem of abnormal body fat distribution and a high risk of insulin resistance, diabetes, high triglycerides, and fatty liver, but each type may have its own pattern of which body areas are affected and how severe the metabolic complications are.

Causes and contributing factors

In FPLD5, there is one main cause: a change in the CIDEC gene. Most other items below are not true causes of the disease itself but factors that influence how early it appears, how strong it is, or how many complications develop.

1. CIDEC gene mutation (main cause)
The basic cause of FPLD5 is a harmful mutation in both copies of the CIDEC gene. This mutation stops the CIDEC protein from working correctly, so fat cells cannot fuse their fat droplets and store fat properly under the skin.

2. Homozygous loss-of-function variant
Many patients have the same harmful change in the CIDEC gene on both chromosomes (homozygous variant). This severe loss of function leads to marked fat loss from the limbs and strong metabolic problems, including insulin-resistant diabetes and fatty liver.

3. Compound heterozygous CIDEC variants
Some people may inherit two different harmful CIDEC variants, one from each parent (compound heterozygous). Together, these can damage CIDEC function enough to cause the same partial lipodystrophy picture and related metabolic disease.

4. Autosomal recessive inheritance pattern
Because FPLD5 is autosomal recessive, parents who are healthy carriers but share the same CIDEC mutation have a higher chance of having a child with the disease. When both parents carry one non-working copy, each pregnancy has a 25% chance of producing an affected child.

5. Consanguinity (parents related by blood)
In some families, parents are related (for example, cousins). This makes it more likely that they both carry the same rare CIDEC mutation, so the chance that their children will inherit two non-working copies and develop FPLD5 becomes higher.

6. Defective lipid droplet fusion in fat cells
CIDEC protein normally helps small fat droplets inside fat cells join together and grow. When CIDEC is defective, lipid droplets stay small and unstable. This defect lowers the capacity of fat cells to store triglycerides, pushing fat to other tissues like liver and muscle, where it causes damage.

7. Reduced subcutaneous fat storage capacity
Because under-skin fat cells cannot store enough fat, the body “overflows” fat into other places. This reduced capacity itself is not a separate cause, but it is a direct effect of the gene defect and a key step that leads to insulin resistance, high triglycerides and fatty liver.

8. Visceral fat preservation and central fat gain
In FPLD5, visceral fat (fat around the organs) is relatively preserved compared with subcutaneous fat in the limbs. This central fat is metabolically more harmful and strongly linked to insulin resistance and cardiovascular risk if total fat can no longer be stored safely under the skin.

9. Insulin resistance as a downstream driver
Insulin resistance develops because fat is stored in the wrong places, such as liver and muscle. While insulin resistance is not the primary cause of FPLD5, once it appears, it helps drive high blood sugar, type 2 diabetes, and high triglycerides, which worsen overall health.

10. High-calorie, high-fat diet in a person with CIDEC mutation
People with FPLD5 are very sensitive to extra calories, especially from sugar and fat. A high-calorie diet overloads the limited storage space in subcutaneous fat, so excess fat goes to the liver and blood, speeding up diabetes, fatty liver, and pancreatitis.

11. Sedentary lifestyle
Lack of regular physical activity reduces the body’s ability to use glucose and fat for energy. In someone with a CIDEC mutation, inactivity can worsen insulin resistance, raise blood sugar and triglycerides, and bring on symptoms at a younger age.

12. Puberty and hormonal changes
Many familial partial lipodystrophy syndromes become obvious around puberty. Hormonal changes increase body fat and shift where fat is stored, so the abnormal pattern of fat loss from the limbs and fat gain in the trunk becomes more noticeable during teenage years.

13. Pregnancy-related metabolic stress
In women with FPLD5, pregnancy increases insulin resistance and fat turnover. This can unmask or worsen diabetes, high triglycerides and fatty liver, making the disease more visible and more dangerous during and after pregnancy.

14. Co-existing overweight or obesity of central type
Some people with familial partial lipodystrophy also have general weight gain, especially around the abdomen. In these cases, the mix of genetic fat distribution defect and additional central obesity increases the risk of diabetes, fatty liver and cardiovascular disease.

15. Other genetic modifiers (LMNA, PPARG, etc.)
Common or rare variants in other genes involved in fat storage (such as LMNA, PPARG, PLIN1, LIPE, AKT2, CAV1) may not cause FPLD5 on their own, but they may slightly change how severe the phenotype is in a person who already has CIDEC mutations.

16. Epigenetic changes (DNA methylation and others)
Changes in gene regulation, such as DNA methylation patterns, can affect how strongly genes related to fat storage and insulin signaling are expressed. In FPLD, these epigenetic effects may modify how the disease shows in different people with the same CIDEC mutation.

17. Long-term use of certain medicines (for example, steroids)
Medicines like glucocorticoids (steroids) can increase insulin resistance and raise blood sugar and triglyceride levels. In people with FPLD5, these drugs can significantly worsen existing metabolic problems and trigger complications such as pancreatitis.

18. Poorly controlled type 2 diabetes
Once diabetes develops, if blood sugar stays high for a long time, it can further damage blood vessels, nerves and organs. In FPLD5, chronic poor glycemic control can speed up liver disease, heart disease and neuropathy, adding to the burden created by the CIDEC defect.

19. Non-alcoholic fatty liver disease progression
Fatty liver can progress to liver inflammation and scarring (steatohepatitis and fibrosis). In FPLD5, this progression is driven by the underlying fat storage defect and high triglycerides, and makes liver-related symptoms and test abnormalities worse.

20. High blood pressure and cardiovascular strain
High blood pressure commonly develops in people with familial partial lipodystrophy and increases the strain on the heart and vessels. In FPLD5, the combination of hypertension, diabetes and high triglycerides greatly increases the risk of cardiovascular disease and related complications.

Symptoms and signs

1. Loss of fat from legs and buttocks
People with FPLD5 often notice that their legs, buttocks and sometimes lower trunk look very lean, even when they are not trying to lose weight. The skin may look tight over the muscles, and veins may be more visible because of the lack of soft fat padding.

2. Muscular-looking arms and legs
Because subcutaneous fat is missing, the limbs can look very muscular or “athletic,” even in people who do not exercise a lot. This appearance is due to reduced fat, not increased muscle mass, and may appear in late childhood or during adolescence.

3. Extra fat around neck, face and trunk
At the same time, fat may be kept or increased around the neck, chin, and inside the abdomen. This can cause a rounded face or a thick neck and a big belly, which contrasts with the thin limbs, creating an uneven body shape.

4. Dark, velvety skin in folds (acanthosis nigricans)
Many patients develop dark, thick, velvety patches of skin, especially behind the neck, under the arms, and in the groin. This change, called acanthosis nigricans, is a visible sign of severe insulin resistance and is common in CIDEC-related lipodystrophy.

5. Insulin resistance
Even before diabetes appears, the body’s cells may not respond well to insulin. People may feel hungrier, gain weight in the wrong places, or show abnormal glucose levels on tests, even when fasting blood sugar is still in the normal range.

6. Type 2 diabetes mellitus
Over time, insulin resistance often leads to type 2 diabetes. Patients may notice increased thirst, frequent urination, tiredness and blurred vision. Blood tests show high fasting glucose, high HbA1c, or abnormal results on an oral glucose tolerance test.

7. High triglycerides (hypertriglyceridemia)
Triglyceride levels in the blood can become very high because the body cannot store fat safely in subcutaneous tissue. This can cause milky-looking blood samples and increases the risk of acute pancreatitis, which is a painful and serious complication.

8. Pancreatitis and severe abdominal pain
Some people with FPLD5 suffer episodes of pancreatitis due to extremely high triglycerides. They may feel sudden severe upper abdominal pain, nausea and vomiting, and may need hospital care. Repeated episodes can damage the pancreas and worsen diabetes.

9. Fatty liver (hepatic steatosis)
Because fat cannot be stored well under the skin, it builds up in the liver. This fatty liver often causes no early symptoms, but people may feel vague right-upper-abdominal discomfort or tiredness. Blood tests and scans show fat inside the liver cells.

10. Enlarged liver (hepatomegaly)
As more fat collects, the liver can become enlarged. Doctors may feel the edge of the liver below the right rib cage on examination, and imaging confirms enlargement. An enlarged liver can cause a feeling of fullness or pressure in the upper abdomen.

11. High blood pressure (hypertension)
High blood pressure is common in familial partial lipodystrophy and adds to the risk of heart and kidney disease. Many people do not feel symptoms at first, so regular blood pressure checks are important to detect and treat hypertension early.

12. Irregular menstrual periods in women
Women with severe insulin resistance and lipodystrophy may have irregular periods, reduced fertility, or signs that resemble polycystic ovary syndrome, such as excess body hair and acne. These changes come from hormone imbalances related to insulin resistance.

13. Low blood levels of leptin and adiponectin
Leptin and adiponectin are hormones made by fat tissue. In FPLD5, their levels are often low because there is not enough healthy subcutaneous fat. Patients do not feel this directly, but low leptin and adiponectin worsen appetite control, insulin resistance and fat metabolism.

14. Tiredness and reduced energy
Chronic high blood sugar, fatty liver, and hormonal disturbances can make people feel tired, weak, or less able to exercise. This tiredness is often non-specific but affects quality of life and may improve when metabolic control is better.

15. Emotional and body-image distress
The unusual body shape, with thin limbs and central fat, plus chronic health problems, can cause emotional stress, low self-esteem and anxiety. Psychological support is often needed to help people cope with this long-term rare disease.

Diagnostic tests

Doctors use a mix of physical examination, simple manual tests, blood and tissue tests, electrodiagnostic studies and imaging to diagnose FPLD5, check how severe it is, and look for complications. Genetic testing for CIDEC is crucial to confirm the specific type.

Physical examination tests

1. Full body fat distribution examination
The doctor looks carefully at the pattern of fat across the body. In FPLD5, they see loss of fat in the limbs and femorogluteal region, with relative preservation or increase of fat in the abdomen, neck and axillae. This visual pattern is a key clinical clue to familial partial lipodystrophy.

2. Measurement of weight, height and body mass index (BMI)
Basic measurements are taken to calculate BMI. In FPLD5, BMI may be normal or only mildly raised, which can be misleading because it does not show the abnormal fat pattern. These measures still help follow overall weight trends over time.

3. Waist and hip circumference with waist-to-hip ratio
A tape measure is used to check waist and hip size, and the waist-to-hip ratio is calculated. In FPLD5, this ratio is often high because the waist is relatively large and the hips and buttocks are very lean. A high ratio signals central fat accumulation and increased metabolic risk.

4. Skin and mucosa examination
The doctor inspects the skin for acanthosis nigricans (dark, velvety patches), areas of fat loss, and possible xanthomas (fatty skin bumps from high triglycerides). These visible signs strongly suggest severe insulin resistance and lipid disorders, which fit with FPLD.

Manual clinical tests

5. Skinfold thickness measurement with calipers
A handheld caliper is used to measure skinfold thickness at standard points (for example, triceps, thigh, abdomen). In FPLD5, skinfolds over the limbs and buttocks are very thin, while abdominal skinfolds may be relatively thicker, documenting the uneven fat distribution in a simple way.

6. Liver palpation and percussion
The doctor feels and taps the right upper abdomen to check if the liver is enlarged and firm. In FPLD5, hepatomegaly from fatty liver is common, and the edge of the liver may be felt below the rib margin, which later can be confirmed by imaging.

7. Abdominal examination for pancreatitis tenderness
During acute abdominal pain, the doctor presses the upper abdomen to look for tenderness, guarding or rebound. In a patient with FPLD5 and very high triglycerides, such findings raise concern for pancreatitis and guide urgent blood tests and imaging.

8. Foot and nerve examination (monofilament or light touch tests)
Simple bedside tests using a light touch or monofilament on the feet check for reduced sensation. In people with FPLD5 and longstanding diabetes, decreased feeling suggests peripheral neuropathy, a common complication of chronic high blood sugar.

Laboratory and pathological tests

9. Fasting plasma glucose test
A blood sample is taken after an overnight fast to measure glucose level. In FPLD5, fasting glucose may be normal early on but often becomes high as insulin resistance worsens. This test is a basic tool for diagnosing and monitoring diabetes.

10. Oral glucose tolerance test (OGTT)
The patient drinks a standard glucose solution, and blood samples are taken over two hours. In familial partial lipodystrophy, the OGTT often shows an exaggerated rise in glucose, revealing early insulin resistance or diabetes even when fasting values are borderline.

11. Hemoglobin A1c (HbA1c)
This blood test shows the average blood sugar over the previous two to three months. In people with FPLD5, HbA1c is used to diagnose diabetes and to monitor how well blood sugar is controlled with diet, exercise and medicines.

12. Fasting lipid profile (triglycerides and cholesterol)
A fasting blood test measures triglycerides, total cholesterol, HDL and LDL. FPLD5 often shows very high triglycerides and low HDL, patterns that increase the risk of pancreatitis and heart disease and are important for both diagnosis and treatment planning.

13. Liver function tests (ALT, AST, GGT, ALP, bilirubin)
These blood tests assess liver cell injury and bile flow. In people with fatty liver due to lipodystrophy, liver enzymes such as ALT and AST may be mildly or moderately elevated, signaling ongoing liver stress and the need for closer follow-up or imaging.

14. Serum insulin and C-peptide levels
Measuring insulin and C-peptide helps doctors understand how much insulin the pancreas is still making and how strong insulin resistance is. In FPLD5, insulin and C-peptide may be high because the pancreas is trying hard to overcome resistance, even before overt diabetes appears.

15. Serum leptin and adiponectin levels
Specialized labs can measure leptin and adiponectin, hormones produced by fat cells. Levels are often low in lipodystrophy compared with the degree of fat-related disease, which supports the diagnosis and may guide decisions about possible leptin-based therapies in some lipodystrophy patients.

Electrodiagnostic tests

16. Electrocardiogram (ECG)
An ECG records the electrical activity of the heart. In FPLD5, it is used to screen for heart problems related to hypertension, diabetes and abnormal blood fats. It may show signs of heart strain or previous silent heart damage that needs further work-up.

17. Nerve conduction studies
In people with long-standing diabetes and symptoms such as numbness or burning in the feet, nerve conduction tests measure the speed and strength of nerve signals. Slowed conduction confirms peripheral neuropathy, a common complication of severe metabolic disease in lipodystrophy.

Imaging tests

18. Abdominal ultrasound
Ultrasound uses sound waves to create images of the liver, pancreas and other organs. In FPLD5, ultrasound often shows a bright, enlarged liver due to fat accumulation and can sometimes detect changes in the pancreas during episodes of pancreatitis.

19. Liver MRI or CT scan
Magnetic resonance imaging (MRI) or computed tomography (CT) provides more detailed pictures of the liver and can more accurately measure liver fat content and any scarring. These scans help assess how advanced fatty liver disease is in patients with FPLD5.

20. Whole-body DEXA or MRI body-composition scan
Dual-energy X-ray absorptiometry (DEXA) or whole-body MRI can map how much fat is present in different body regions. In FPLD5, these scans clearly show loss of fat in limbs and buttocks and preserved or increased fat in the trunk, supporting the diagnosis and helping to distinguish FPLD5 from simple obesity.

Non-pharmacological treatments (therapies and other approaches)

1. Medical nutrition therapy with a specialist dietitian
   A dietitian who understands lipodystrophy can design a personal meal plan that matches your age, weight, blood sugars and triglycerides. The goal is to avoid strong glucose and triglyceride spikes after meals while still giving enough calories and nutrients for daily life. A structured plan can reduce fatty liver, improve insulin sensitivity and lower pancreatitis risk over time by limiting refined carbohydrates and controlling total fat, especially when combined with regular follow-up and blood tests.[3]

2. Low-glycemic index, high-fiber eating pattern
   Choosing foods that raise blood sugar slowly (whole grains, pulses, non-starchy vegetables, whole fruits) helps reduce insulin resistance and protects pancreatic beta cells. High fiber also improves satiety, supports healthy gut bacteria and may modestly reduce cholesterol and triglycerides. For many lipodystrophy patients, this pattern is similar to a Mediterranean-style or DASH-style diet, adapted to individual tolerance and culture.[4]

3. Moderate restriction of saturated fat and simple sugars
   FPLD5 patients commonly develop very high triglycerides and fatty liver. Reducing sugary drinks, sweets, white flour, and limiting saturated fat from fatty meat and deep-fried foods lowers triglyceride production in the liver. This approach can reduce risk of pancreatitis and improve response to lipid-lowering medicines.[5]

4. Regular aerobic exercise
   Brisk walking, cycling, swimming or similar activities on most days of the week improves insulin sensitivity, lowers blood pressure and triglycerides, and helps the liver handle fat better. Even 30 minutes per day, split into shorter sessions, can significantly improve cardiometabolic health when maintained long term.[6]

5. Resistance and strength training
   Light weights, resistance bands or body-weight exercises build and preserve muscle. More muscle means better glucose disposal and stronger physical function. This is especially useful in lipodystrophy, where body composition is abnormal and muscle may appear prominent but still benefit from structured training under guidance.[7]

6. Weight and waist-circumference monitoring
   Even if overall weight looks “normal”, FPLD5 patients can have high visceral fat and serious metabolic risk. Regular measurement of weight and waist, together with liver and lipid tests, helps detect early worsening and allows lifestyle or medication adjustments before complications such as pancreatitis or cirrhosis appear.[8]

7. Limiting or avoiding alcohol
   Alcohol adds extra calories, increases triglycerides and directly damages the liver. In someone with fatty liver from lipodystrophy, even small amounts can accelerate fibrosis or trigger pancreatitis. Many experts recommend total avoidance or very strict limits after individual assessment.[9]

8. Smoking cessation
   Smoking multiplies the risk of heart attack and stroke in people who already have insulin resistance, hypertension and dyslipidemia. Quitting improves circulation, reduces inflammation and works together with lipid and blood pressure control to protect the heart and brain.[10]

9. Structured diabetes self-management education
   Many FPLD5 patients eventually develop severe insulin-resistant diabetes. Learning how to monitor blood glucose, count carbohydrates, recognize symptoms of hypo- and hyperglycemia and adjust lifestyle improves control and reduces emergency visits. Education should be adapted to age, culture and literacy level.[11]

10. Regular liver health monitoring and lifestyle for fatty liver
    Ultrasound, elastography and liver blood tests help track fatty liver and fibrosis, which are common in lipodystrophy. Losing excess visceral fat, reducing fructose and alcohol, and controlling diabetes and triglycerides can slow or reverse some liver changes.[12]

11. Blood-pressure control through lifestyle
    Salt reduction, weight management, regular exercise and stress control help lower blood pressure, often reducing the dose or number of antihypertensive drugs needed. In FPLD5, this is important to prevent kidney damage and cardiovascular events, which are major long-term risks.[13]

12. Psychological counselling and support
    Changes in body shape, chronic illness and the fear of complications can lead to anxiety, depression or low self-esteem. Counselling helps patients and families cope emotionally, make sustainable lifestyle changes and stick to complex treatment plans. Support groups for rare diseases can also reduce isolation.[14]

13. Genetic counselling for patients and families
    Because FPLD5 is a hereditary disorder linked to CIDEC mutations, genetic counselling helps families understand inheritance patterns, carrier testing options and reproductive choices. It also supports early diagnosis in relatives who may show mild or early signs but have not yet developed severe metabolic disease.[15]

14. Education on pancreatitis risk and early symptom recognition
    Extremely high triglycerides can cause acute pancreatitis. Teaching patients to recognize severe upper abdominal pain, vomiting and fever and to seek urgent care can be life-saving. Lifestyle and medication adherence aimed at keeping triglycerides controlled is key prevention.[16]

15. Vaccination to protect the liver and general health
    Vaccines against hepatitis A and B, influenza, pneumococcus and COVID-19 may be recommended because liver disease, diabetes and chronic illness can increase the risk of severe infections. Maintaining vaccination schedules is a simple but powerful prevention tool.[17]

16. Sleep hygiene and treatment of sleep apnea
    Poor sleep and untreated sleep apnea worsen insulin resistance, blood pressure and cardiovascular risk. Simple measures like regular sleep times, avoiding heavy late meals and evaluation for snoring or witnessed apneas can support better metabolic control.[18]

17. Stress-reduction techniques (mindfulness, relaxation)
    Chronic stress raises cortisol and can worsen blood sugar and blood pressure. Relaxation exercises, breathing techniques, yoga adapted to ability, or mindfulness programs can be helpful add-ons, as long as they do not replace medical care.[19]

18. Foot care and cardiovascular risk education in diabetes
    When severe diabetes develops, nerve damage and circulation problems can lead to foot ulcers and infections. Daily inspection of the feet, proper footwear and regular podiatry visits greatly reduce this risk. Education about heart-attack and stroke symptoms is also important.[20]

19. Regular comprehensive follow-up in a specialized clinic
    Because FPLD5 affects many organs, coordinated care by endocrinologists, hepatologists, cardiologists, dietitians and geneticists is ideal. Scheduled visits allow early detection of complications and timely adjustment of lifestyle and medication plans.[21]

20. Participation in registries and clinical research (where available)
    Enrolling in lipodystrophy registries and ethically approved research gives patients access to expert review and sometimes to new therapies. It also helps scientists understand FPLD5 better and develop targeted treatments for future patients.[22]

---

Drug treatments

Most of these drugs are approved for diabetes, high lipids or related problems, not specifically “for FPLD5”. Doctors adapt them to the patient’s situation. Information below is educational; always follow your own doctor’s plan.

1. Metreleptin (Myalept – leptin analogue)
   Metreleptin replaces or supplements leptin, a hormone made by fat cells. It is FDA-approved for generalized lipodystrophy and some severe lipodystrophy cases with very low leptin and hard-to-control diabetes and triglycerides, but its use in FPLD5 is specialized and often off-label. It is given as a daily subcutaneous injection based on body weight. It improves HbA1c, triglycerides and liver enzymes in many patients but carries risks such as anti-metreleptin antibodies and possible lymphoma, so it is restricted to certified prescribers with careful monitoring.[23]

2. Insulin glargine (Lantus and similar – long-acting insulin)
   Insulin glargine is a long-acting insulin analog used once daily to provide “background” insulin for people with diabetes. In FPLD5, severe insulin resistance often means high doses are needed, sometimes combined with rapid-acting insulin at meals. The aim is to keep fasting and overall glucose in target range while minimizing hypoglycemia. Dose is titrated gradually under medical supervision.[24]

3. Rapid-acting mealtime insulins (e.g., insulin lispro, aspart)
   These insulins act quickly after injection to cover the rise in blood sugar from meals. They are often used with basal insulin in people with marked insulin resistance. Patients are taught to match the dose to carbohydrate intake and pre-meal glucose readings, with careful monitoring to avoid lows.[25]

4. Metformin (biguanide class)
   Metformin is usually the first-line oral drug for type 2 diabetes. It reduces glucose production by the liver and improves insulin sensitivity. In lipodystrophy, metformin can lower HbA1c, modestly improve weight and possibly benefit fatty liver. It is taken with meals, starting with low doses to reduce stomach upset, and is avoided in severe kidney or liver disease.[26]

5. Pioglitazone (Actos – thiazolidinedione)
   Pioglitazone is an insulin-sensitizing drug that acts through PPAR-γ to improve glucose uptake in muscle and fat and reduce liver glucose production. It can be useful in insulin-resistant diabetes, including some lipodystrophy patients, but may cause weight gain, fluid retention, heart-failure worsening and fracture risk. Typical doses are 15–45 mg orally once daily, adjusted by the physician.[27]

6. GLP-1 receptor agonists (e.g., liraglutide, semaglutide)
   GLP-1 agonists increase insulin release when glucose is high, slow stomach emptying and reduce appetite. Case reports suggest benefit in familial partial lipodystrophy with diabetes and obesity, improving HbA1c, weight and lipids. They are given as daily or weekly injections and may cause nausea and rarely pancreatitis, so they need close monitoring.[28]

7. SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin)
   These oral drugs make the kidneys pass more glucose into urine, lowering blood sugar independent of insulin. They also offer heart and kidney protection in high-risk diabetics. Side effects include genital infections, dehydration and rare ketoacidosis, so they must be used carefully in lean or insulin-deficient people.[29]

8. Fenofibrate (Tricor, Fenoglide – fibrate class)
   Fenofibrate strongly lowers triglycerides and modestly raises HDL cholesterol by activating PPAR-α. It is often used when triglycerides are very high to reduce pancreatitis risk. Typical daily doses vary by product and kidney function; dose is reduced in renal impairment. Possible side effects include liver-enzyme rise, gallstones and muscle problems, especially with statins.[30]

9. High-intensity statins (e.g., atorvastatin, rosuvastatin)
   Statins are first-line drugs for lowering LDL cholesterol and preventing heart attack and stroke. In FPLD5, where cardiovascular risk is high, statins are often essential, sometimes combined with fibrates or other agents. They are taken once daily, and muscle or liver side effects are monitored with blood tests and symptom checks.[31]

10. Prescription omega-3 fatty acid ethyl esters
    Highly purified EPA/DHA products at high doses can lower very high triglycerides and may reduce pancreatitis risk. They are usually added to fibrates and statins when triglycerides remain elevated. The main side effects are fishy aftertaste and possible bleeding risk at very high doses, especially with anticoagulants.[32]

11. Ezetimibe (cholesterol-absorption inhibitor)
    Ezetimibe blocks absorption of cholesterol from the intestine and is often combined with a statin when LDL goals are not reached. It has a relatively mild side-effect profile and can help reduce cardiovascular risk further in high-risk lipodystrophy patients.[33]

12. ACE inhibitors or ARBs (e.g., lisinopril, losartan)
    These blood-pressure drugs also protect the kidneys and heart in people with diabetes. They are recommended when hypertension or kidney involvement appears. Side effects include cough (with ACE inhibitors), high potassium and rare angioedema, requiring regular blood tests.[34]

13. Beta-blockers (e.g., carvedilol, bisoprolol)
    Beta-blockers are used for heart failure, coronary artery disease or certain arrhythmias. In FPLD5 patients with these complications, they reduce mortality and symptoms but must be balanced carefully in people with very low heart rate or asthma.[35]

14. Antiplatelet agents (aspirin, clopidogrel)
    In patients with established cardiovascular disease or very high risk, low-dose aspirin or other antiplatelets may be used to reduce clot formation. These medicines increase bleeding risk, so they are prescribed only after careful assessment.[36]

15. Non-insulin injectables for diabetes (e.g., GLP-1/GIP combinations)
    Newer injectable agents combining GLP-1 and GIP hormones can lower HbA1c and weight significantly in type 2 diabetes and obesity. Although not studied specifically in FPLD5, they may be considered by specialists in selected patients with severe insulin resistance and excess visceral fat.[37]

16. Bile-acid sequestrants (e.g., colesevelam)
    These drugs lower LDL cholesterol and can modestly improve glycemic control in some people with type 2 diabetes. They are sometimes used when statins alone are not enough or not tolerated. Side effects include constipation and interference with absorption of other medicines.[38]

17. Ursodeoxycholic acid (for selected liver disease)
    In some forms of cholestatic or fatty liver disease, ursodeoxycholic acid may improve liver enzyme levels and bile flow. Its role in FPLD5-related liver disease is limited and should be decided by a hepatologist.[39]

18. Vitamin E at high doses for non-diabetic NASH (selected cases)
    In carefully chosen non-diabetic patients with biopsy-proven NASH, high-dose vitamin E has shown some benefit. In diabetic lipodystrophy, evidence is weaker, and risks such as bleeding and prostate cancer need consideration, so this is a specialist decision.[40]

19. Pancreatitis management drugs (intravenous fluids, analgesics, etc.)
    When pancreatitis occurs from very high triglycerides, treatment includes hospital care with aggressive fluids, pain control and sometimes insulin infusion or apheresis to quickly lower triglycerides. This is an emergency and not a routine outpatient therapy.[41]

20. Experimental agents in clinical trials
    Various experimental drugs are being studied in lipodystrophy and severe metabolic disease, including novel insulin sensitizers and agents targeting liver fat. For FPLD5, these are only available in research settings, and no specific “FPLD5 drug” is yet approved.[42]

---

Dietary molecular supplements

These supplements are not proven cures for FPLD5. They may support metabolic health when used safely under medical guidance.

1. Omega-3 fatty acids (fish-oil capsules) – Often 1–4 g/day of EPA/DHA is used to lower triglycerides and support heart health, especially when diet and prescription drugs are not enough.[43]

2. Vitamin D – Correcting deficiency with daily or weekly vitamin D can improve bone health and may modestly support immune and metabolic function, especially in patients with limited sun exposure.[44]

3. Vitamin E (physiologic doses) – Lower-dose vitamin E from diet or supplements may act as an antioxidant, but high doses should only be used if specialists recommend it for specific liver indications.[45]

4. Soluble fiber (psyllium, oat-bran) – Taken with plenty of water, soluble fiber can help lower LDL cholesterol and post-meal glucose spikes, improving satiety and bowel regularity.[46]

5. Magnesium – In people with proven low magnesium, supplementation may support blood-pressure control and glucose handling; excess doses can cause diarrhea or be unsafe in kidney disease.[47]

6. Probiotics – Selected probiotic strains may modestly improve metabolic markers and fatty liver in some studies, but evidence is still emerging, and products vary widely in quality.[48]

7. Alpha-lipoic acid – An antioxidant sometimes used for diabetic nerve pain; it may improve oxidative stress and insulin sensitivity slightly but should be used cautiously due to limited data in lipodystrophy.[49]

8. Chromium – Often marketed for glucose control, chromium may have small effects on insulin sensitivity in some people but is not a substitute for standard diabetes therapy.[50]

9. Coenzyme Q10 – Used for muscle symptoms in some patients on statins and as an antioxidant; evidence for strong metabolic benefit is limited, but it is sometimes tried when muscle symptoms are problematic.[51]

10. Multivitamin tailored to liver and diabetes – A balanced multivitamin that avoids excessive fat-soluble vitamins can help cover basic micronutrient needs when diets are restricted, but it should be selected by a clinician or dietitian.[52]

---

Immunity-booster, regenerative and stem-cell-related drugs

There are no approved stem-cell or “immune-boosting” drugs specifically for FPLD5. Current approaches are supportive and experimental:

1. Metreleptin as systemic metabolic support – By correcting leptin deficiency in selected lipodystrophy patients, metreleptin improves glucose and lipid metabolism, indirectly supporting organ health, but it is not an immune booster or stem-cell therapy and carries serious risks.[53]

2. Modern cardiometabolic drugs as organ-protective agents – GLP-1 agonists, SGLT2 inhibitors and statins reduce cardiovascular and renal risk and can be considered “regenerative-supportive” because they help preserve organ function, though they do not regenerate fat cells or liver tissue.[54]

3. Investigational gene-based approaches – Research is exploring gene therapy and molecular pathways related to CIDEC and other lipodystrophy genes, but these are at early stages and not available as routine treatment.[55]

4. Experimental stem-cell therapies for liver disease or diabetes – Mesenchymal stem cell infusions and other approaches are under study in severe liver disease and diabetes, but safety and long-term benefit remain uncertain, so they should only be accessed inside regulated clinical trials.[56]

5. Vaccination and infection prevention as “immune support” – The safest way to support immunity is full vaccination, good nutrition, adequate sleep, and strict control of diabetes, which reduce infection risk and improve recovery.[57]

6. Avoidance of unregulated “stem-cell” or immune-booster products – Many clinics and online products claim to regenerate organs or boost immunity but lack evidence and may be dangerous or illegal. People with rare diseases like FPLD5 are especially targeted and should be protected from such offers.[58]

---

Surgeries (Procedures and why they are done)

1. Cosmetic liposuction or lipectomy of fat-accumulation areas – In some lipodystrophy patients with distressing fat accumulation in the neck or trunk, plastic surgeons may remove localized fat. This can improve body image but does not treat metabolic disease and may need repeat procedures.[59]

2. Bariatric (metabolic) surgery – In FPLD5 patients with severe obesity and uncontrolled diabetes despite optimal medical therapy, bariatric surgery may be considered. It can dramatically improve glucose control and cardiovascular risk, but requires lifelong follow-up and nutritional support.[60]

3. Liver transplantation – Rarely, patients with advanced cirrhosis from fatty liver may need liver transplant. This is major surgery with significant risks and is reserved for end-stage liver failure, not early disease.[61]

4. Pancreatic or biliary surgery for severe pancreatitis complications – If pancreatitis causes necrosis, infected collections or biliary obstruction, surgery or minimally invasive procedures may be necessary. The goal is to treat life-threatening complications, not FPLD5 itself.[62]

5. Cardiovascular procedures (stents, bypass surgery) – Because long-standing diabetes and dyslipidemia can cause coronary artery disease, some patients eventually need angioplasty, stents or bypass surgery to treat blocked heart arteries.[63]

---

Preventions

1. Early diagnosis of FPLD5 and metabolic monitoring.[64]

2. Lifelong healthy diet focused on low-GI, high-fiber foods and limited sugars and saturated fats.[65]

3. Regular physical activity combining aerobic and strength exercises.[66]

4. Tight but safe control of blood glucose and blood pressure with lifestyle and drugs.[67]

5. Aggressive management of high triglycerides to prevent pancreatitis.[68]

6. Regular liver imaging and blood tests to track fatty liver and fibrosis.[69]

7. Smoking avoidance and minimal or no alcohol use.[70]

8. Vaccinations and infection-prevention measures.[71]

9. Regular follow-up in experienced centers and adherence to treatment.[72]

10. Genetics-based family screening for early metabolic risk management.[73]

---

When to see doctors urgently or promptly

You should seek urgent medical help if you have:

• Sudden severe upper abdominal pain, especially with vomiting or fever (possible pancreatitis).

• Chest pain, shortness of breath, sudden weakness in the face or limbs, or trouble speaking (possible heart attack or stroke).

• Very high blood sugar with extreme thirst, frequent urination, nausea, deep breathing or confusion.

You should arrange routine or early appointments when:

• Blood sugars or triglycerides are drifting higher.

• You notice new liver, kidney or blood-pressure abnormalities on tests.

• You are planning pregnancy or have questions about family risk.

---

What to eat and what to avoid

What to eat (5 points)

1. Plenty of non-starchy vegetables (leafy greens, cucumbers, okra, cauliflower).

2. Whole grains and pulses instead of white rice or white bread.

3. Lean protein such as fish, skinless poultry, eggs, tofu and lentils.

4. Healthy fats in small amounts from nuts, seeds and olive or mustard oil.

5. Whole fruits (not juices), spaced through the day.

What to avoid or limit (5 points)

1. Sugary drinks, sweetened tea, juice and sweets.

2. Deep-fried and fast foods high in saturated and trans fats.

3. Large portions of white rice, white bread and refined flour products.

4. Heavy alcohol intake and binge drinking.

5. “Miracle” weight-loss or detox products without evidence.

---

Frequently asked questions (FAQs)

1. Is FPLD5 the same as other familial partial lipodystrophies?
   No. FPLD5 is a specific subtype caused by mutations in the CIDEC gene and often behaves differently from LMNA-, PPARG- or PLIN1-related forms, though many metabolic problems overlap.[74]

2. Can FPLD5 be cured?
   At present, there is no cure that restores normal fat distribution or fully fixes the gene change. Treatment focuses on preventing and controlling complications and improving quality of life.[75]

3. Will every person with FPLD5 develop diabetes?
   Many, but not all, affected people develop insulin-resistant diabetes, often in adolescence or adulthood. Lifestyle, other genes and early treatment strongly influence the timing and severity.[76]

4. Is metreleptin always needed?
   No. Metreleptin is reserved for selected patients with severe, difficult-to-control metabolic disease and very low leptin, and is given only in specialized programs due to serious risks.[77]

5. Can I get pregnant if I have FPLD5?
   Many women with FPLD can have pregnancies, but they are high-risk because of diabetes, hypertension and liver disease. Pre-pregnancy counselling and specialist care are very important.[78]

6. What is the life expectancy with FPLD5?
   Because FPLD5 is extremely rare, long-term data are limited. However, strict control of diabetes, blood pressure and lipids and avoidance of smoking and heavy alcohol probably improve survival significantly.[79]

7. Is FPLD5 always inherited, or can it be a new mutation?
   FPLD5 is usually inherited in an autosomal pattern, but new mutations in CIDEC can occur. Genetic testing can clarify this in each family.[80]

8. Should my family members be tested?
   Close relatives may benefit from genetic counselling and, when appropriate, genetic and metabolic testing so that early lifestyle and medical interventions can start if needed.[81]

9. Does body-building or fitness training cause or cure FPLD5?
   No. Muscular appearance in FPLD5 is due to lack of subcutaneous fat, not necessarily extra muscle. Exercise is healthy and recommended, but it does not fix the underlying genetic cause.[82]

10. Can diet alone control FPLD5?
    Diet is essential but rarely enough by itself once diabetes and severe dyslipidemia develop. Most patients need a combination of lifestyle changes and medicines.[83]

11. Are over-the-counter “fat burners” or herbal products safe?
    These products are not recommended. They often lack evidence, can harm the liver or heart and may interact with prescription medicines.[84]

12. Can children be diagnosed with FPLD5?
    Yes, some children show abnormal fat distribution and early insulin resistance. Specialist evaluation and genetic testing help confirm the diagnosis and start monitoring early.[85]

13. Is exercise safe if I have heart or liver problems?
    In most cases, carefully planned exercise is beneficial, but intensity should be adapted to your condition and agreed with your doctors.[86]

14. Will I always need insulin?
    Some people manage with tablets and lifestyle for a time, while others require insulin earlier. Needs may change over the years; regular review with your diabetes team is essential.[87]

15. Where can I find expert care or more information?
    Rare-disease organizations and lipodystrophy networks, as well as national endocrine or metabolic centers, often list specialist clinics and patient resources for lipodystrophy and FPLD.[88]

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: January 26, 2025.